What is Zosano Pharma Financial Strength?
Zosano Pharma has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Zosano Pharma did not have earnings to cover the interest expense.
Zosano Pharma's debt to revenue ratio for the quarter that ended in Mar. 2022 was 11.45.
As of today, Zosano Pharma's Altman Z-Score is 0.00.
Competitive Comparison of Zosano Pharma's Financial Strength
For the Biotechnology subindustry, Zosano Pharma's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zosano Pharma's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zosano Pharma's Financial Strength distribution charts can be found below:
* The bar in red indicates where Zosano Pharma's Financial Strength falls into.
Zosano Pharma Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Zosano Pharma's Interest Expense for the
months ended in Mar. 2022 was $-0.07 Mil. Its Operating Income for the
months ended in Mar. 2022 was $-7.38 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $2.66 Mil.
Zosano Pharma's Interest Coverage for the quarter that ended in Mar. 2022 is
| Zosano Pharma did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Zosano Pharma's Debt to Revenue Ratio for the quarter that ended in Mar. 2022 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Zosano Pharma has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zosano Pharma (Zosano Pharma) Business Description
Traded in Other Exchanges
N/A
Address
34790 Ardentech Court, Fremont, CA, USA, 94555
Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.
Executives
| Christine Matthews |
officer: Chief Financial Officer |
C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555 |
| Steven Lo |
director, officer: Chief Executive Officer |
C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010 |
| Donald J Kellerman |
officer: VP, Clinical Dev & Med Affairs |
INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466 |
| Elaine Yang |
director |
C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555 |
| Kenneth Greathouse |
director |
3260 WHIPPIE ROAD, UNION CITY CA 94587 |
| Hayley Lewis |
officer: See Remarks |
C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304 |
| Kathy M. Mcgee |
director |
C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
| Linda S Grais |
director |
86 ALEJANDRA AVE, ATHERTON CA 94027 |
| Joseph P Hagan |
director |
3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
| Kleanthis G Xanthopoulos |
director |
9050 CAMINO SANTA FE, SAN DIEGO CA 92121 |
| John Peter Walker |
director |
126 ISABELLA AVE, ATHERTON CA 94027 |
| Aisling Capital Partners Iv, Lp |
10 percent owner |
888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
| Aisling Capital Partners Iv Llc |
10 percent owner |
888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
| Aisling Capital Iv, Lp |
10 percent owner |
888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
| Andrew N Schiff |
10 percent owner |
PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
Zosano Pharma (Zosano Pharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZSANQ has been successfully added to your